Evidence map›Paper›PMID 41221200›Full record

ArticleMDM policy & practice

Treatment Preferences among Patients with Hormone-Sensitive Prostate Cancer in France, Spain, China, South Korea, and Japan: A Discrete-Choice Experiment.

Juan Marcos Gonzalez, Arijit Ganguli, Alicia K Morgans, Bertrand F Tombal, Sebastien J Hotte, Hiroyoshi Suzuki, Daniel Ng, Charles D Scales, Matthew J Wallace, Jui-Chen Yang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in MDM policy & practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Juan Marcos GonzalezDepartment of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.ORCID https://orcid.org/0000-0002-5386-0907
Arijit GanguliMedical Affairs, Astellas Pharma Inc., Northbrook, IL, USA.
Alicia K MorgansDana-Farber Cancer Institute, Boston, MA, USA.
Bertrand F TombalCliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
Sebastien J HotteDepartment of Oncology, McMaster University and Juravinski Cancer Centre, Hamilton, ON, Canada.
Hiroyoshi SuzukiDepartment of Urology, Toho University Sakura Medical Center, Sakura City, Chiba, Japan.
Daniel NgMedical Affairs, Astellas Pharma Singapore Pte Ltd, Singapore, Singapore.
Charles D ScalesDepartment of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.
Matthew J WallaceDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.ORCID https://orcid.org/0000-0002-6250-4998
Jui-Chen YangDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.ORCID https://orcid.org/0000-0001-8229-6578
Daniel J GeorgeDepartment of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Highlights: Our study demonstrates that discrete-choice experiments (DCEs) are valuable for capturing health-related preferences among patients with prostate cancer.Contextual factors, such as efficacy and the country-specific health care system in which choices are presented, influence the ability to pool DCE data across countries.DCEs have the potential to enhance patient-centered care, shaping the future of evidence-based health care decision making.

Indexed as

adverse effectsdiscrete-choice experimenthigh-risk localized prostate cancermetastatic hormone-sensitive prostate cancerprostate cancertreatmenttreatment choices

Identifiers

PMID41221200
PMCPMC12598092

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.